breast cancer drug candidates. Pharmacognosy Journal 2021;13:1143–9. https://doi.org/10.5530/pj.2021.13.147.

[20] Chen Y, Lu M, Lin M, Gao Q. Network pharmacology and molecular docking to elucidate the common mechanism of hydroxychloroquine treatment in lupus nephritis and IgA nephropathy. Lupus 2024;33. https://doi.org/10.1177/09612033241230377.

[21] Wu D, Hong L, Xu S, Zhong Z, Gong Q, Wang Q, et al. Integrating network pharmacology and experimental validation via PPAR signaling to ameliorate rheumatoid arthritis: Insights from Corydalis Decumbentis Rhizoma (Xiatianwu). Fitoterapia 2025;183. https://doi.org/10.1016/j.fitote.2025.106541.

[22] Boonyong C, Powthong P. Prediction of primary human targets and toxicity mechanisms of imidacloprid using integrative In Silico approaches. Toxicol Rep 2026;16. https://doi.org/10.1016/j.toxrep.2026.102199.

[23] Jurowski K, Niżnik Ł, Frydrych A, Kobylarz D, Noga M, Krośniak A, et al. Toxicological profile of Acovenoside A as an active pharmaceutical ingredient – prediction of missing key toxicological endpoints using in silico toxicology methodology. Chem Biol Interact 2025;408. https://doi.org/10.1016/j.cbi.2025.111404.